All In Biotech

NDA 018664 · Anbex

Iosat

Potassium Iodide · Oral

Last checked: Nov 20, 2026Latest source record: Dec 20, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1982

Oct 14, 1982

Approved uses

1

Original approval plus efficacy supplements

Registered trials

549

97 Phase 3, 39 recruiting

FAERS reports

1,413

1,272 serious, 385 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 3, 2025.

Uses Helps prevent radioactive iodine from getting into the thyroid gland during a nuclear radiation emergency. Use along with other emergency measures recommended by public officials. INDICATIONS IOSAT™ (Potassium Iodide tablets, USP) is a thyroid blocking medicine that is used in a nuclear radiation emergency only.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 14, 1982 Original approval
2 products under this application
  • IOSAT · POTASSIUM IODIDE 65MG · TABLET, ORAL · Over-the-counter
  • IOSAT · POTASSIUM IODIDE 130MG · TABLET, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Iodide" as an intervention, any sponsor and status, largest first.

All 549 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea276
  • haemorrhagic stroke257
  • sepsis257
  • dyspnoea256
  • fatigue250
  • fall247
  • headache243
  • tachycardia242
  • cardio-respiratory arrest241
  • insomnia240
  • dizziness239
  • cough238

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20044
20054
20069
200714
200814
200916
201013
201114
201212
201326
201428
201538
201648
201750
201862
201976
2020104
202191
2022186
2023162
2024263
2025133
202646

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 303 on PubMed

Sponsor: Anbex

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.